로딩 중…
지수 로딩 중…
Starling Oncology Institute Inc. Common Stock
STLN· NASDAQ
$6.63+7.28%
2026-10-09
Financials
Valuation Metrics
Starling Oncology Institute Inc. Common Stock's Market Cap is $676M. Ranked #2646 of 3,115 in US market (top 85%), #1131 of 1,464 on NASDAQ (top 77%) by Market Cap.
Investment Metrics(as of 2026-10-09)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $676M | US#2,646/3,115 |
| Revenue | $587M | US#2,171/3,115 |
| Net Income | $-36M | US—/3,115 |
| Total Assets | $178M | US#3,004/3,115 |
| Net Assets | $-25M | US#2,932/3,115 |
| Employees | 641 | US#2,158/3,115 |
| Value | ||
| P/S | 1.15x | US#809/3,115 |
| FCF Yield | -0.49% | US—/3,115 |
| Profitability | ||
| ROA | -20.36% | US#2,795/3,115 |
| Op. Margin | -4.44% | US#2,440/3,115 |
| Financial Health | ||
| Total Debt | $104M | US#2,433/3,115 |
| FCF | $-3M | US#2,336/3,115 |
| Cash | $41M | US#2,653/3,115 |
| Current Ratio | 1.36x | US#1,823/3,115 |
| Performance | ||
| 1M Return | 5.41% | US#263/3,115 |
| From 52W High | -7.01% | US#522/3,115 |
| 1Y MDD | -12.34% | US#94/3,115 |
| Trading | ||
| Volume | 1,831,879 shares | US#1,452/3,115 |
| Trading Value | $12M | US#2,546/3,115 |
| Per Share | ||
| EPS | $-0.36 | US—/3,115 |
| BPS | $-0.24 | US—/3,115 |
Company Info
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.